2015
MHC class II-disparate heart but not skin allografts accelerate recipient cardiovascular disease (TRAN1P.934)
Zhou J, yi T, Qin L, Ali R, Li Q, Jiao Y, Li G, Zhang J, Sadeghi M, Pober J, Tellides G. MHC class II-disparate heart but not skin allografts accelerate recipient cardiovascular disease (TRAN1P.934). The Journal Of Immunology 2015, 194: 140.16-140.16. DOI: 10.4049/jimmunol.194.supp.140.16.Peer-Reviewed Original ResearchSkin allograftsCardiovascular diseaseAllograft rejectionCardiac allograftsHeart allograftsDonor miceSkin graftsMHC classAtherosclerotic lesionsApoE-/- mouse modelEarly activation marker CD69End-stage organ failureCD4 T cellsWeeks post transplantationActivation marker CD69Larger atherosclerotic lesionsHeart isograftsCardiac isograftsOrgan failurePost transplantationIL-12ACardiac functionElevated mRNA levelsEffective therapyOrgan transplantation
1997
Blockade of CD2-LFA-3 interactions protects human skin allografts in immunodeficient mouse/human chimeras
Sultan P, Schechner J, McNiff J, Hochman P, Hughes C, Lorber M, Askenase P, Pober J. Blockade of CD2-LFA-3 interactions protects human skin allografts in immunodeficient mouse/human chimeras. Nature Biotechnology 1997, 15: 759-762. PMID: 9255790, DOI: 10.1038/nbt0897-759.Peer-Reviewed Original ResearchConceptsSkin graftsLFA-3Human T-cell infiltrationIsotype-matched control antibodyT cell infiltrationSkin graft rejectionHuman skin graftsHuman skin allograftsCD2-LFA-3 interactionHuman LFA-3Microvascular injuryGraft rejectionLeukocyte infiltrationSkin allograftsImmune modulatorsControl antibodyInjury modelImmunodeficient miceImmune reactionsMouse/human chimeraMurine mAbsCD2 interactionPrincipal ligandGraftInjury